Clinical trials: Phenylephrine
Healthy
Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects
To assess the absorption of 30 mg Lefradafiban in two formulations, each under physiological conditions and with 40 mg Pantoprazole
- Trial name
- NCT02264106
- Testing
- Lefradafiban tablet, Lefradafiban double chamber sachet, Pantoprazole
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet coadministered with canagliflozin in healthy…
- Trial name
- NCT02865668
- Testing
- Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Insomnia
Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women
This study has been designed to compare the effects of melatonin with those of drugs (temazepam and zolpidem) regularly prescribed for the treatment of insomnia, in healthy, middle-aged volunteers.
- Trial name
- NCT00940550
- Testing
- Prolonged-release melatonin, Temazepam, Zolpidem
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Migraine
A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
This is a single-center, open-label, randomized, four-way crossover study. Subjects will receive the four study treatments once, followed by in-clinic monitoring and extensive pharmacokinetic analysis.
- Trial name
- NCT03978403
- Testing
- M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches), M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups), M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zosano Pharma Corporation
Healthy
A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers
The purpose of this study is to assess the effects of single and multiple doses of domperidone on the QTc interval duration in healthy adult volunteers at domperidone doses of 10 mg four times a day (q.i.d.) and 20 mg q.i.d.
- Trial name
- NCT01643889
- Testing
- Treatment A (domperidone 10 mg), Treatment B (domperidone 20 mg), Treatment D (moxifloxacin)
- Where
- Belgium
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects
The study is intended to demonstrate that macitentan does not have an effect on cardiac repolarization exceeding the threshold of regulatory concern after repeated administration of daily oral doses of 10 and 30 mg to healthy…
- Trial name
- NCT02050802
- Testing
- Moxifloxacin 400 mg, Macitentan 10 mg, Macitentan 30 mg
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Actelion
Healthy
Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers
Study to demonstrate average bioequivalence between a 400 mg ibuprofen extrudate tablet (Test) and a 400 mg ibuprofen lysinate tablet (Dolormin extra ®; reference 1) under fasted conditions.
- Trial name
- NCT02183012
- Testing
- Ibuprofen extrudate, Ibuprofen lysinate, Ibuprofen
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood
The main objective of this trial is to investigate: the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs.
- Trial name
- NCT06193811
- Testing
- Avenciguat (BI 685509) (intended commercial formulation (iCF)), Avenciguat (BI 685509) (trial formulation 2 (TF2)), esomeprazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication) and relative bioavailability of 3 newly developed abiraterone acetate tablet formulations compared with the current commercial…
- Trial name
- NCT01640093
- Testing
- Abiraterone acetate, 250 mg (uncoated, current commercial tablet), Abiraterone acetate, 500 mg (coated, reformulated tablet), Abiraterone acetate, 250 mg (coated, reformulated tablet)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteer
Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval
The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.
- Trial name
- NCT04898907
- Testing
- ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Moxifloxacin Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Angion Biomedica Corp
Healthy
A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants
The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram [mg] once-daily) and supratherapeutic (150 mg once-daily) doses…
- Trial name
- NCT02152332
- Testing
- JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, Moxifloxacin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteer
A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval
This is a two-part study to evaluate the safety and tolerability of supratherapeutic doses of RO7033877 (Part 1) and to investigate the effect of RO7033877 on the QTc interval in healthy volunteers (Part 2).
- Trial name
- NCT02165332
- Testing
- Part 1: SAD RO7033877, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work…
- Trial name
- NCT00783003
- Testing
- GSK233705 and GW642444, GW642444, GSK233705
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid Abuse Nondependent
Nasal Human Abuse Potential of PTI-821
The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.
- Trial name
- NCT03475862
- Testing
- PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Smoking Cessation
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
The primary objective of this trial is to assess the effects of cytisinicline at therapeutic and supratherapeutic doses on cardiac repolarization relative to placebo in healthy adult subjects who are smokers.
- Trial name
- NCT05566288
- Testing
- Cytisinicline, Moxifloxacin
- Where
- Portugal
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Achieve Life Sciences
Moderate Pain
A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets
The aim of this study is to assess disintegration of the new Aspirin disintegrating tablets
- Trial name
- NCT03225352
- Testing
- 500 mg acetylsalicylic acid (Aspirin, BAYE4465), 1000 mg acetylsalicylic acid (Aspirin, BAYE4465), 400 mg ibuprofen(Nurofen)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation
The purpose of this study is to (1) evaluate the effect of caloric intake on the pharmacokinetics of a single dose of a 330 mg pregabalin controlled release tablet relative to a 300 mg pregabalin immediate release capsule…
- Trial name
- NCT01080612
- Testing
- 330 mg pregabalin controlled release, 300 mg pregabalin immediate release
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects
A clinical study to assess next-day driving performance following evening administrations of ACT-541468 in middle-aged and elderly subjects
- Trial name
- NCT03892902
- Testing
- ACT-541468, Zopiclone 7.5 mg
- Where
- Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Heart Failure
A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects
AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator. AZD9977 is a partial antagonist and partial agonist in reporter gene assays and has a different interaction pattern with the MR compared to eplerenone.
- Trial name
- NCT03804645
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca